246 related articles for article (PubMed ID: 28900511)
1. A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.
Liang Y; Li S; Wang X; He B; He B; Dai W; Zhang H; Wang X; Wang Y; Zhou D; Zhang Q
Theranostics; 2017; 7(13):3306-3318. PubMed ID: 28900511
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers.
Liang Y; Li S; Wang X; Zhang Y; Sun Y; Wang Y; Wang X; He B; Dai W; Zhang H; Wang X; Zhang Q
J Control Release; 2018 Apr; 275():129-141. PubMed ID: 29408580
[TBL] [Abstract][Full Text] [Related]
3. α
Zhong P; Meng H; Qiu J; Zhang J; Sun H; Cheng R; Zhong Z
J Control Release; 2017 Aug; 259():176-186. PubMed ID: 27986551
[TBL] [Abstract][Full Text] [Related]
4. A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy.
Meng H; Zou Y; Zhong P; Meng F; Zhang J; Cheng R; Zhong Z
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28464449
[TBL] [Abstract][Full Text] [Related]
5. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
[No Abstract] [Full Text] [Related]
6. Peptide-Drug Conjugate-Based Nanocombination Actualizes Breast Cancer Treatment by Maytansinoid and Photothermia with the Assistance of Fluorescent and Photoacoustic Images.
Sun Y; Liang Y; Dai W; He B; Zhang H; Wang X; Wang J; Huang S; Zhang Q
Nano Lett; 2019 May; 19(5):3229-3237. PubMed ID: 30957499
[TBL] [Abstract][Full Text] [Related]
7. α
Zhong P; Gu X; Cheng R; Deng C; Meng F; Zhong Z
Int J Nanomedicine; 2017; 12():7913-7921. PubMed ID: 29138558
[TBL] [Abstract][Full Text] [Related]
8. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
[TBL] [Abstract][Full Text] [Related]
9. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
10. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering.
Guo Z; He B; Jin H; Zhang H; Dai W; Zhang L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2014 Jul; 35(23):6106-17. PubMed ID: 24794924
[TBL] [Abstract][Full Text] [Related]
11. Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug-Drug Conjugate with High Drug Loading and Antitumor Efficacy.
Song Q; Wang X; Wang Y; Liang Y; Zhou Y; Song X; He B; Zhang H; Dai W; Wang X; Zhang Q
Mol Pharm; 2016 Jan; 13(1):190-201. PubMed ID: 26629710
[TBL] [Abstract][Full Text] [Related]
12. Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies.
Shi S; Zhou M; Li X; Hu M; Li C; Li M; Sheng F; Li Z; Wu G; Luo M; Cui H; Li Z; Fu R; Xiang M; Xu J; Zhang Q; Lu L
J Control Release; 2016 Aug; 235():1-13. PubMed ID: 27235150
[TBL] [Abstract][Full Text] [Related]
13. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly.
Xie K; Song S; Zhou L; Wan J; Qiao Y; Wang M; Xie H; Zhou L; Zheng S; Wang H
Int J Pharm; 2019 Feb; 556():159-171. PubMed ID: 30553007
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
15. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
16. Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.
Chang CY; Wang MC; Miyagawa T; Chen ZY; Lin FH; Chen KH; Liu GS; Tseng CL
Int J Nanomedicine; 2017; 12():279-294. PubMed ID: 28115846
[TBL] [Abstract][Full Text] [Related]
17. Redox-responsive amphiphilic camptothecin prodrug nanoparticles for targeted liver tumor therapy.
Lu L; Li B; Lin C; Li K; Liu G; Xia Z; Luo Z; Cai K
J Mater Chem B; 2020 May; 8(17):3918-3928. PubMed ID: 32227058
[TBL] [Abstract][Full Text] [Related]
18. Design of integrin α
Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
[TBL] [Abstract][Full Text] [Related]
19. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
[TBL] [Abstract][Full Text] [Related]
20. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor.
Hamano N; Negishi Y; Fujisawa A; Manandhar M; Sato H; Katagiri F; Nomizu M; Aramaki Y
Int J Pharm; 2012 May; 428(1-2):114-7. PubMed ID: 22421321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
